Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gamascab
- Development stage
- Unknown
- Lead developer
- Nulife Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Gamascab is a topical anti-parasitic lotion containing 1% lindane (gamma benzene hexachloride), manufactured by NuLife Pharmaceuticals. It is primarily used for the treatment of scabies and lice infestations. Lindane functions as a neurotoxin by interacting with the gamma-aminobutyric acid (GABA) receptor-chloride channel complex. Specifically, it binds to the picrotoxin binding site of the GABAA receptor, acting as a non-competitive antagonist that inhibits chloride ion flux. This leads to hyperexcitability of the parasite's central nervous system, resulting in convulsions and death of both the mites and their eggs. The product has been used clinically for over 30 years.
- Brand names
- Gamascab
- Other names
- LindaneGamma benzene hexachloride
02
Targets
GABAA (Gamma-aminobutyric acid receptor)
Beyond the preview
Go deeper on Gamascab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gamascab.